Cell Signaling Technology

Product Pathways - Growth Factors/Cytokines

Mouse Vascular Endothelial Growth Factor-164 (mVEGF164 ) #5211

Request pricing for multi-milligram amounts.

Source

Recombinant mouse VEGF164 (mVEGF164) Ala205-Arg368 (Accession #NP_033531) was expressed in human 293 cells at Cell Signaling Technology.

Molecular Characterization

Recombinant mVEGF164 contains no "tags" and the nonglycosylated protein has a calculated MW of 19,278. DTT-reduced protein migrates as a 24-31 kDa polypeptide. Lower mobility in SDS-PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 38-44 kDa protein. The expected amino-terminal APTTE of recombinant mVEGF164 was verified by amino acid sequencing.

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mVEGF164. All lots are greater than 98% pure.

Bioactivity

The bioactivity of recombinant mVEGF164 was determined in a cell proliferation assay using HUVEC. The ED50 of each lot is between 1-5 ng/ml.

Coomassie Gel

Coomassie Gel

The purity of recombinant mVEGF164 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mVEGF164 and staining overnight with Coomassie Blue.

Bioactivity

Bioactivity

The proliferation of HUVEC treated with increasing concentrations of mVEGF164 was assessed. After 72-hour treatment with mVEGF164 cells were incubated with a tetrazolium salt and the OD450-OD650 was determined.

Western Blotting

Western Blotting

Western blot analysis of extracts from HUVEC untreated or treated with mVEGF164 for 15 minutes, using Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060 (upper) and Akt1 (C73H10) Rabbit mAb #2938 (lower).


Endotoxin

Less than 0.01 ng endotoxin/1μg mVEGF164.

Formulation

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mVEGF164. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

Background

VEGF164 is one of many splice variants of the mouse VEGF-A gene, and is one amino acid shorter than its human counterpart, VEGF165 (1,2). VEGF164 is produced by a number of cells including endothelial cells, macrophages and T cells (1,2). VEGF164 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability (1,2). Gene expression is induced by hypoxia, inflammatory cytokines and oncogenes (1,2). VEGF164 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix (1-3). VEGFR1 and VEGFR2 are the receptor tyrosine kinases for VEGF164 (2). NRP-1 and NRP-2 may function as co-receptors and enhance VEGFR2 signaling (2-3). Binding of VEGF164 to VEGFR1 and VEGR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and Paxillin (2).

  1. Haigh, J.J. (2008) Organogenesis 4, 247-56.
  2. Takahashi, H. and Shibuya, M. (2005) Clin Sci (Lond) 109, 227-41.
  3. Neufeld, G. et al. (1999) FASEB J 13, 9-22.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products